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Chronic neuropathic pain and depression are often comorbid. Ketamine has been used to treat refractory pain. There is emerging
evidence for use in depression.We present a case of a pediatric patient who was successfully treated with subanesthetic intravenous
ketamine infusion for chronic neuropathic pain and suicidality.
1. Introduction
Neuropathic pain is often difficult to treat despite multi-
modal analgesia. Similarly, refractory depression has limited
treatment options available. Intravenous ketamine infusion
has been increasingly used for the treatment of neuropathic
pain. Several recent trials have also shown that intravenous
ketamine infusion has a rapid antidepressant effect [1, 2].
There are especially limited research and evidence on the
efficacy of the dual treatment of major depression and
neuropathic pain in the pediatric population. We present a
case of an adolescent with severe depression, suicidality, and
neuropathic leg pain who failed multiple antidepressant and
analgesic modalities who was successfully treated with sub-
anesthetic intravenous ketamine infusion. To our knowledge
this is the first reported case with dual use of intravenous
ketamine infusion to treat neuropathic pain and suicidal
depression in the pediatric patient.
The patient’s healthcare proxy (mother) provided written
consent for publication as the patient is a minor.
2. Case Description
A 14-year-old female presented to an outpatient psychia-
trist with severe depression and suicidal ideation. She was
admitted to the pediatric psychiatric unit for evaluation and
treatment.
Her medical history was significant for anxiety, depres-
sion with multiple suicide attempts, postconcussive syn-
drome, chronicmigraines, and previous diagnosis of complex
regional pain syndrome of the lower extremities.While being
admitted for depression and suicidality, she also complained
of exacerbation of her bilateral leg pain, which significantly
limited her mobility and worsened her mood.
She was admitted two months prior for bilateral gen-
eralized neuropathic leg pain which limited her mobility.
A lumbar magnetic resonance image (MRI) was unre-
markable. She tried multiple classes of pain medications
including acetaminophen, nonsteroidal anti-inflammatory
agents, tricyclic antidepressants, gabapentinoids, antiepilep-
tics, and opioids. Additional interventions included acupunc-
ture, physical therapy, occupational therapy, guided imagery
therapy, and epidural steroid injection.
Upon readmission for suicidality, the pain management
team was consulted. On her psychiatric evaluation, patient
had a depressed, flat affect endorsing suicidality. The patient
reported despair regarding her chronic pain as well as
flashbacks to a previous concussion after a fall several years
prior with subsequent development of her neuropathic type
pain. She had also reported several instances of self-injurious
behaviors including cutting and two suicide attempts with
a shoelace and pillowcase. She was placed on continuous
observation. The patient’s chronic outpatient psychiatric
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medications include fluoxetine and aripiprazole. While she
was an inpatient, the patientwas also trialed onbupropion but
was discontinued due to increased agitation and irritability.
She also reported severe burning bilateral leg pain. In addi-
tion, she described her pain in terms of “shooting”, reporting
painful paresthesias, dysesthesias, and hyperalgesia as well as
a “numbness” characterization to her bilateral leg pain, which
followed a neuropathic pattern.
Her lumbar spine was mildly tender to palpation, but
her neurological exam was otherwise intact. While her
characterization of pain was neuropathic in nature, she did
not meet the criteria for complex regional pain syndrome.
There were no allodynic features, vasomotor, pseudomotor,
or tropic changes on exam. Despite her prescribed regimen
of pregabalin, ibuprofen, acetaminophen, lidocaine 5% patch,
tizanidine, and subsequently oxycodone as needed, her pain
continued. She had also been tried previously on morphine
with also minimal efficacy. The patient also underwent a
ten-day trial of duloxetine with minimal improvement and
reported worsening severe depressive symptoms, suicidal
ideations, and neuropathic pain. It was then recommended to
start an intravenous ketamine infusion which was theorized
to have a more rapid clinical onset and effect.
Patient was transferred to the pediatric intensive care
unit for intravenous ketamine infusion andmonitoring. Prior
to starting intravenous ketamine infusion, her leg pain was
rated 7/10 on the numerical rating scale (NRS, 0-10 with
10 being the worst pain) of burning quality. There was no
weakness or changes in sensation, though there was limited
mobility secondary to pain. Intravenous ketamine infusion
was started at 7micrograms/kilogram/minute (mcg/kg/min).
The ketamine infusion was used 24 hours per day for the
entire duration of the treatment with ketamine infusion. The
total dose was titrated based on the specific mcg/kg/min.The
patient’s weight (72 kg) was used for the dosing calculation.
The patient remained hemodynamically stable with no
dysphoria or hallucinations. On day one of intravenous
ketamine infusion, the patient had significant improvement
of her depressive symptoms, as noted by psychiatry and
painmanagement teams, and themaximumNRS throughout
the day was 6/10. On day two, she reported less pain
in her legs with a maximum NRS of 5/10, and signifi-
cant improvement in her mood with no further suicidal
ideations. On day three, intravenous ketamine infusion
was increased to 8 micrograms/kilogram/minute; however
physical exam revealed nystagmus and visual changes and
was decreased to 7 micrograms/kilogram/minute. Patient’s
pain maximum NRS score remained at 5/10. On day four,
maximum NRS score reduced to 4/10 and self-reported 70%
pain relief since initiation of intravenous ketamine infusion.
She also had functional improvement in her legs and was
able to ambulate freely. On day five, dosage was titrated
down to 4 micrograms/kilogram/minute with maximum
NRS score of 0/10 and sustained improvement in mood.
Intravenous ketamine infusion was further reduced to 2
micrograms/kilogram/minute and discontinued that same
day. She was able to tolerate physical therapy and maintain
analgesia. Psychiatric reassessment determined her to be
no longer at suicide risk, and she was discharged with no
immediate sequelae and was placed on chronic aripiprazole,
topiramate, and lithium by her outpatient psychiatrist.
The patient had five months of symptom relief after her
first intravenous ketamine infusion. She was readmitted five
months later with repeated suicide attempts, depression, and
worsening bilateral upper and lower extremity neuropathic
pain, though with decreased baseline NRS. Due to her
dramatic improvement and sustained relief with intravenous
ketamine infusion during her last admission, as well as the
lack of other successful treatment options, she was again
admitted to the pediatric intensive care unit for five days
of intravenous ketamine infusion with resolution of her
neuropathic pain and suicidal/depressive symptoms allowing
for discharge home without any immediate sequelae.
3. Discussion
Toour knowledge this is the first reported successful pediatric
use of intravenous ketamine infusion for the dual treatment
of depression with suicidality and chronic neuropathic pain.
There is one recent report on the use of ketamine for chronic
pain and depression in an adult, but none in the pediatric
population [1].
In this case the diagnosis of neuropathic pain was made
based on clinical descriptors and history. As noted in a recent
review, by Gilron et al., there is no absolute pathognomonic
sign or symptom of neuropathic pain [3]. Consequently
the patient’s diagnosis was made based on her descriptors
and symptoms in setting of persistent pain that seemed to
reflect a neuropathic pain pattern rather than a nociceptive,
nonneuropathic painful condition. The authors of this case
acknowledge that there are screening tools used for diagnosis
of neuropathic pain and quantitative objective sensory test-
ing. These were not used in our patient, especially in light of
her ongoing psychiatric, severe, comorbid symptoms.
Neuropathic pain is nerve pain secondary to peripheral
or central nervous injury or dysfunction. It often presents as
spontaneous burning or lancinating pain. Other symptoms
include allodynia, hyperesthesia, hyperalgesia, and the symp-
toms are typically persistent even after the primary insult
has resolved. The current management for the treatment
of neuropathic pain is limited due to minimal evidence of
efficacy. Traditional first-line agents include gabapentinoids,
tricyclic antidepressants, or serotonin-norepinephrine reup-
take inhibitors (SNRIs) [4].
Opioids have had mixed efficacy for neuropathic pain.
The evidence supporting use for chronic noncancer pain
in children and adolescents is low and limited at best
[5]. Furthermore, opioids are considered second/third-line
therapy because of their questionable long-term efficacy as
well as the risks of opioid related adverse effects which
commonly include sedation, gastrointestinal effects including
constipation and nausea/vomiting. Additionally respiratory
depression can occur. Also, opioid misuse and addiction
potential is a serious consideration [3]. Given our patient’s
comorbid advanced psychiatric state, chronic opioid therapy
and further titration were not deemed to be a safe and viable
option.
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Combination therapy is often required due to noneffi-
cacy of monotherapy. Additional nonpharmacological treat-
ment includes cognitive behavioral therapy, physical therapy,
biofeedback, and transcutaneous electrical nerve stimulation
(TENS) [6]. Despite a multimodal treatment approach, neu-
ropathic pain can be refractory, andmultiple novel targets for
neuropathic pain are being studied [7].
Themechanism of neuropathic pain differs for peripheral
and central pain. Peripheral sensitization occurs due to an
injury to axons of a peripheral nerve. This insult leads to
spontaneous activation, abnormal excitability, and increased
sensitivity to chemical, mechanical, and thermal stimuli
[8]. When this occurs in the spinothalamic tract, central
sensitization occurs with increased spontaneous activity and
increased responses to all afferent impulses. This increase in
synaptic efficiency and reduced inhibition lead to a greater
response to nociceptive stimuli [8, 9]. Central sensitization
has been proposed as an explanation for persistent neuro-
pathic pain [10]. There is also the “windup” phenomenon in
which repetitive nociceptive stimuli are potentiated in the
spinal cord causing increased cortical perception of pain [11].
Ketamine is an N-methyl-D-aspartate (NDMA) recep-
tor antagonist. The NMDA receptors are mechanistically
involved with central sensitization [8–10]. Ketamine’s inhi-
bition of the NMDA receptors helps decrease peripheral
and central sensitization, promoting analgesia. In addition,
NMDA receptors are involved in the development of opioid
tolerance. Ketamine’s antagonistic action on NMDA recep-
tors may prevent opioid tolerance in chronic pain patients.
Additional mechanisms of ketamine as an analgesic include
its effect on substance P. Ketamine has been shown to directly
inhibit substance P receptors, which is also increased in
painful hyperalgesic states [12].
The mechanistic role of ketamine in the treatment of
depression, however, is less well defined. First-line treat-
ment for depression is a combination of psychotherapy with
an antidepressant, generally a selective serotonin reuptake
inhibitor (SSRI) based on efficacy and side effect profile
[13]. Additional classes of medications such as serotonin-
norepinephrine reuptake inhibitors, atypical antidepressants,
tricyclic antidepressants, or monoamine oxidase inhibitors
are often used to treat depression refractory to first-line
agents. Electrical convulsive therapy (ECT) is another treat-
ment modality for severe depression refractory to pharmaco-
logic agents. While ECT provides a rapid response and thus
has utility in the acute setting, it requires general anesthesia
and has complications including somatic injury and dental
trauma, as well as confusion and amnesia [14].
As an alternative, ketamine has emerged for treatment
of major depressive disorder with or without suicidality.
Several trials demonstrated a large reduction in the severity of
depression within 24 hours of intravenous ketamine infusion
with lasting antidepressant efficacy [2]. A systematic litera-
ture review also demonstrated reduction in suicidal ideation
for treatment resistant depression with the use of ketamine
[15]. An additional benefit is the rapid antidepressant effect
compared with most first-line antidepressant medications.
The antidepressant mechanism of ketamine is unclear at
this point but may involve ketamine’s NMDA antagonism. In
fact, citalopram and fluoxetine, both SSRIs, have been shown
to have functional effects of NMDA receptor blockade [16].
Ketamine, by inhibiting NMDA receptors, leads to increased
production of brain-derived neurotrophic factor (BDNF) and
mammalian target of rapamycin complex 1 (mTORC1), both
of which are associated with synaptogenesis and have been
shown to be decreased in patients withmajor depression [16].
One limitation of using ketamine is the higher level
monitoring. Due to state regulations, at our institution,
patients receiving an intravenous ketamine infusion require
an intensive care unit or step down unit for the first 24
hours; it is therefore a resource burden [17]. Furthermore, the
long-term cognitive effects and optimal subanesthetic dosing
and duration for the dual treatment of neuropathic pain and
depression need to be elucidated. Additionally, the described
subanesthetic intravenous ketamine infusion is an off-label
use in pediatric neuropathic pain and depression.
In summary, we have shown successfully in our trial
that subanesthetic intravenous ketamine infusion has the
potential for emerging use in the pediatric population for
neuropathic pain and depression given its rapid-onset antide-
pressant and analgesic effects as well as favorable safety profile
at subanesthetic dosing.
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